Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Current Leases: 2019-2025

Historic Current Leases for Pharming Group N.V (PHAR) over the last 5 years, with Sep 2025 value amounting to $28.1 million.

  • Pharming Group N.V's Current Leases rose 1.10% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 1.10%. This contributed to the annual value of $2.9 million for FY2024, which is 18.53% down from last year.
  • Pharming Group N.V's Current Leases amounted to $28.1 million in Q3 2025, which was up 2.15% from $27.5 million recorded in Q2 2025.
  • In the past 5 years, Pharming Group N.V's Current Leases registered a high of $31.1 million during Q1 2023, and its lowest value of -$2.6 million during Q2 2023.
  • Moreover, its 3-year median value for Current Leases was $27.7 million (2024), whereas its average is $20.9 million.
  • Data for Pharming Group N.V's Current Leases shows a peak YoY increase of 188,604.28% (in 2023) and a maximum YoY decrease of 61.23% (in 2023) over the last 5 years.
  • Pharming Group N.V's Current Leases (Quarterly) stood at $2.4 million in 2021, then spiked by 43.24% to $3.5 million in 2022, then increased by 4.36% to $3.6 million in 2023, then declined by 18.53% to $2.9 million in 2024, then grew by 1.10% to $28.1 million in 2025.
  • Its last three reported values are $28.1 million in Q3 2025, $27.5 million for Q2 2025, and $26.5 million during Q1 2025.